AstraZeneca has announced results of a study showing that the safety profile of Symbicort budesonide/formoterol inhalation aerosol 320/9 µg twice daily was similar to that for a budesonide alone pMDI 320 µg twice daily in African-American patients with moderate-to-severe asthma. The data from the 52-week randomized, double-blind Phase IIIb safety study were published in the May 1st online edition of The Journal of Allergy & Clinical Immunology.
AstraZeneca Associate Medical Director Frank Trudo commented, “These findings provide important information about the use of Symbicort in African-American patients with persistent asthma, and may help guide healthcare professionals considering treatment therapies for their appropriate patients with asthma. This trial is part of AstraZeneca’s commitment to studying Symbicort in patient populations with disproportionate asthma prevalence.”
Read the AstraZeneca press release.
Read the JACI abstract.
